-
H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
Unicycive Therapeutics (UNCY) PT Lowered to $2.50 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022
-
H.C. Wainwright Reiterates Buy Rating, $9 Price Target on Unicycive Therapeutics (UNCY)
-
UPDATE: H.C. Wainwright Starts Unicycive Therapeutics (UNCY) at Buy

